Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
